Ohad Mazor
Weizmann Institute of Science
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Ohad Mazor.
Photochemistry and Photobiology | 2004
Ohad Mazor; Alexander Brandis; Vicki Plaks; Eran Neumark; Varda Rosenbach-Belkin; Yoram Salomon; Avigdor Scherz
Abstract WST11 is a novel negatively charged water-soluble palladium-bacteriochlorophyll derivative that was developed for vascular-targeted photodynamic therapy (VTP) in our laboratory. The in vitro results suggest that WST11 cellular uptake, clearance and phototoxicity are mediated by serum albumin trafficking. In vivo, WST11 was found to clear rapidly from the circulation (t1/2 = 1.65 min) after intravenous bolus injection in the mouse, whereas a longer clearance time (t1/2 = 7.5 min) was noted in rats after 20 min of infusion. The biodistribution of WST11 in mouse tissues indicates hepatic clearance (t1/2 = 20 min), with minor (kidney, lung and spleen) or no intermediary accumulation in other tissues. As soon as 1 h after injection, WST11 had nearly cleared from the body of the mouse, except for a temporal accumulation in the lungs from which it cleared within 40 min. On the basis of these results, we set the VTP protocol for a short illumination period (5 min), delivered immediately after WST11 injection. On subjecting M2R melanoma xenografts to WST11-VTP, we achieved 100% tumor flattening at all doses and a 70% cure with 9 mg/kg and a light exposure dose of 100 mW/cm2. These results provide direct evidence that WST11 is an effective agent for VTP and provide guidelines for further development of new candidates.
Photochemistry and Photobiology | 2005
Alexander Brandis; Ohad Mazor; Eran Neumark; Varda Rosenbach-Belkin; Yoram Salomon; Avigdor Scherz
New negatively charged water‐soluble bacteriochlorophyll (Bchl) derivatives were developed in our laboratory for vascular‐targeted photodynamic therapy (VTP). Here we focused on the synthesis, characterization and interaction of the new candidates with serum proteins and particularly on the effect of serum albumin on the photocytotoxicity of WST11, a representative compound of the new derivatives. Using several approaches, we found that aminolysis of the isocyclic ring with negatively charged residues markedly increases the hydrophilicity of the Bchl sensitizers, decreases their self‐association constant and selectively increases their affinity to serum albumin, compared with other serum proteins. The photocytotoxicity of the new candidates in endothelial cell culture largely depends on the concentration of the serum albumin. Importantly, after incubation with physiological concentrations of serum albumin (500–600 μM), WST11 was found to be poorly photocytotoxic (>80% endothelial cell survival in cell cultures). However, in a recent publication (Mazor, O. et al. [2005] Photochem. Photobiol. 81, 342–351) we showed that VTP of M2R melanoma xenografts with a similar WST11 concentration resulted in ∼100% tumor flattening and >70% cure rate. We therefore propose that the two studies collectively suggest that the antitumor activity of WST11 and probably of other similar candidates does not depend on direct photointoxication of individual endothelial cells but on the vascular tissue response to the VTP insult.
Neoplasia | 2003
Dina Preise; Ohad Mazor; Natalia V. Koudinova; Avigdor Scherz; Yoram Salomon
Multidrug resistance (MDR) presents a major obstacle for the successful chemotherapy of cancer. Its emergence during chemotherapy is attributed to a selective process, which gives a growth advantage to MDR cells within the genetically unstable neoplastic cell population. The pleiotropic nature of clinical MDR poses a great difficulty for the development of treatment strategies that aim at blocking MDR at the tumor cell level. Targeting treatment to the nonmalignant vascular network-the lifeline of the tumor-is a promising alternative for the treatment of drug-resistant tumors. The present study demonstrates that MDR in cancer can be successfully circumvented by photodynamic therapy (PDT) using an antivascular treatment protocol. We show that, although P-glycoprotein-expressing human HT29/MDR colon carcinoma cells in culture are resistant to PDT with Pd-bacteriopheophorbide (TOOKAD), the same treatment induces tumor necrosis with equal efficacy (88% vs 82%) in HT29/MDR-derived xenografts and their wild type counterparts, respectively. These results are ascribed to the rapid antivascular effects of the treatment, supporting the hypothesis that MDR tumors can be successfully eradicated by indirect approaches that bypass their inherent drug resistance. We suggest that with progress in ongoing clinical trials, TOOKAD-PDT may offer a novel option for local treatment of MDR tumors.
Luminescence | 2000
Yehudit Amir-Zaltsman; Ohad Mazor; Batya Gayer; Avigdor Scherz; Yoram Salomon; Fortune Kohen
Epidermal growth factor (EGF) receptor (ErbB1)-associated tyrosine kinase inhibitors may act as potential chemotherapeutic agents. In order to assess the inhibitory activity of these compounds, we developed a simple and sensitive assay based on time-resolved fluorescence. In this technique, crude cell lysates bearing the ErbB1 receptor were captured in microtitre plates immobilized with monoclonal anti-ErbB1 antibody SG 565. Subsequently, the phosphotyrosine content of the cell lysates was quantified by a europium-labelled anti-phosphotyrosine antibody. Thus, genistein, a tyrosine kinase inhibitor, was capable of reducing by half the tyrosine phosphorylation caused by the binding of EGF to A431 cells, whereas 6-carboxymethyl genistein did not inhibit protein tyrosine phosphorylation. This assay is simple to perform, does not use radioactive substrates, and can be useful for screening EGF receptor tyrosine kinase inhibitors from natural products or synthetic compounds. Moreover, the assay has a high signal:noise ratio and is suitable for large-scale screening.
Analytical Biochemistry | 2002
Ohad Mazor; Marc Hillairet de Boisferon; Alain Lombet; Anne Gruaz-Guyon; Batya Gayer; Delphine Skrzydelsky; Fortune Kohen; Patricia Forgez; Avigdor Scherz; William Rostène; Yoram Salomon
Journal of Biological Chemistry | 2004
Vicki Plaks; Yehudit Posen; Ohad Mazor; A. Brandis; Avigdor Scherz; Yoram Salomon
Archive | 2003
Avigdor Scherz; Alexander Brandis; Ohad Mazor; Yoram Salomon; Hugo Scheer
Archive | 2017
Alexander Brandis; Avigdor Scherz; Hugo Scheer; Ohad Mazor; Yoram Salomon
Archive | 2003
Avigdor Scherz; Alexander Brandis; Ohad Mazor; Yoram Salomon; Hugo Scheer
Archive | 2003
Avigdor Scherz; Alexander Brandis; Ohad Mazor; Yoram Salomon; Hugo Scheer